Atrial fibrillation (AF) is far more than just an irregular heartbeat—it is the most prevalent cardiac arrhythmia, affecting one in three people over their lifetime. Its impact extends well beyond irregular heart rhythms, standing as a leading cause of stroke, heart failure, and frequent hospital admissions. As its prevalence rises sharply, AF places a heavy burden on patients, healthcare systems, and society.

Pulmonary vein isolation using single-shot catheters is the current gold standard for rhythm control. Yet, despite its widespread use, outcomes remain inconsistent. Physicians rely on limited two-dimensional X-ray imaging without standardized endpoints, leaving lesion quality and durability uncertain. This often results in incomplete ablations, high recurrence rates, and costly repeat procedures that increase risk for patients and strain hospital resources.

AtriAI aims to change this by making the invisible visible. This breakthrough feedback platform provides insight into tissue response revealing lesion quality and expected durability. The benefits are clear: patients face fewer repeat interventions and complications, improving quality of life; physicians gain confidence in effective, complete procedures; and hospitals improve efficiency by reducing costly re-interventions and freeing capacity. For industry partners, AtriAI offers an innovation that strengthens single-shot ablations with clear competitive differentiation.

With tens of millions worldwide affected and growing demand for effective treatment, AtriAI stands poised to transform care—improving lives, increasing hospital efficiency, and driving competitive advantage.

The team includes a senior interventional cardiologist supported by a junior colleague, alongside an expert in algorithm development based at the German Heart Center at Charité (DHZC). Together, they lead this innovative effort to redefine AF care through precision and personalized therapy.

Looking ahead, AtriAI is preparing commercialization through a dedicated spin-off and seeks collaboration with clinical, industrial, and strategic partners to bring this transformative technology to patients worldwide.